ACV meeting #29, 7 January 2022

The 29th meeting of the Advisory Committee on Vaccines (ACV), January 2022.

Date

7 January 2022

The meeting of the Advisory Committee on Vaccines (ACV).

The committee provided advice on one application:

provisional registration of a new vaccine for active immunisation for COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; applicant Biocelect Pty Ltd) that had been under evaluation from February 2021.

Members

Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.

Outcomes

ACV meeting statement, Meeting 29, 7 January 2022

15 March 2022

Meeting statements

Advisory Committee on Vaccines, Meeting 29, 7 January 2022

Topics

Committees and advisory bodies

Meeting of

Advisory Committee on Vaccines (ACV)

Related content

Unique Device Identification (UDI) information session for clinical quality registries

25 May 2026

Webinars

This information session introduces UDI for clinical quality registries. Australia’s UDI framework supports improved identification of medical devices and in vitro diagnostic (IVD) devices.